logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10501559 B1

PDFFull Text
Date of Patent:
Dec. 10, 2019

Filed:

Jun. 09, 2016

T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla

Applicants:

Memorial Sloan Kettering Cancer Center, New York, NY (US);

Eureka Therapeutics, Inc., Emeryville, CA (US);

Inventors:

Nai-Kong V. Cheung, New York, NY (US);

Mahiuddin Ahmed, Verona, NJ (US);

Andres Lopez-Albaitero, New York, NY (US);

Cheng Liu, Emeryville, CA (US);

Su Yan, State College, PA (US);

Jingyi Xiang, Walnut Creek, CA (US);

Hong Liu, El Sobrante, CA (US);

Assignees:

MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US);

EUREKA THERAPEUTICS, INC., Emeryville, CA (US);

Attorneys:

Choate, Hall & Stewart LLP

Brenda Herschbach Jarrell

Tracy L. Vrablik

Primary Examiner:

Stacy B Chen

Int. Cl.
CPC ...
C07K 16/46 (2006.01); C07K 16/08 (2006.01); C07K 16/28 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/468 (2013.01); C07K 16/085 (2013.01); C07K 16/2809 (2013.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); A61K 2039/572 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/32 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/40 (2013.01); C07K 2317/41 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01);
Abstract

Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.

Find Patent Forward Citations

Cheung, Nai-Kong. (2019). T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla (U.S. Patent No. 10501559). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10501559

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…